Lacroix André, Baldacchino Valérie, Bourdeau Isabelle, Hamet Pavel, Tremblay Johanne
Laboratories of Endocrine Pathophysiology, Cellular Biology of Hypertension, and Molecular Medicine, Department of Medicine, Hôtel-Dieu du Centre hospitalier de l'Université de Montréal (CHUM), Montréal H2W 1T8, Canada.
Trends Endocrinol Metab. 2004 Oct;15(8):375-82. doi: 10.1016/j.tem.2004.08.007.
The secretion of cortisol and other steroids from adrenal tumors can be regulated by hormones other than corticotropin following the aberrant expression of several G-protein-coupled receptors (GPCRs). To date, ectopic receptors for gastric inhibitory polypeptide, beta-adrenergic receptor agonists, vasopressin (V(2) and V(3) receptors), 5-hydroxytryptamine (5-HT(7) receptor) and, probably, angiotensin II (AT(1) receptor) have been identified. Either increased expression or altered activity of eutopic receptors for vasopressin (V(1)), luteinizing hormone/human chorionic gonadotropin, 5-HT (5-HT(4) receptor) and leptin might also be involved. One or more aberrant receptors can be present in unilateral tumors and bilateral macronodular adrenal hyperplasia, at either the early subclinical or overt stages of hormone secretion. The identification of aberrant adrenal GPCRs offers the potential for novel pharmacological therapies that either suppress the endogenous ligands or block the receptor with specific antagonists.
在几种G蛋白偶联受体(GPCRs)异常表达后,肾上腺肿瘤中皮质醇和其他类固醇的分泌可受促肾上腺皮质激素以外的激素调节。迄今为止,已鉴定出胃抑制多肽、β-肾上腺素能受体激动剂、血管加压素(V(2)和V(3)受体)、5-羟色胺(5-HT(7)受体)以及可能的血管紧张素II(AT(1)受体)的异位受体。血管加压素(V(1))、促黄体生成素/人绒毛膜促性腺激素、5-羟色胺(5-HT(4)受体)和瘦素的正常受体表达增加或活性改变也可能参与其中。在单侧肿瘤和双侧大结节性肾上腺增生中,在激素分泌的早期亚临床阶段或明显阶段,可能存在一种或多种异常受体。肾上腺异常GPCRs的鉴定为新型药物治疗提供了可能性,这些治疗方法要么抑制内源性配体,要么用特异性拮抗剂阻断受体。